Cargando…

Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study

This study aims to explore the relationship between the doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in the real-world setting, so as to preliminarily evaluate the protective effect induced by COVID-19 vaccination. We conducted a test-negative case-control study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dingmei, Zhong, Jiayi, Xiong, Husheng, Li, Yufen, Guo, Tong, Peng, Bo, Fang, Chuanjun, Kang, Yan, Tan, Jinlin, Ma, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053421/
https://www.ncbi.nlm.nih.gov/pubmed/36992150
http://dx.doi.org/10.3390/vaccines11030566
_version_ 1785015409848614912
author Zhang, Dingmei
Zhong, Jiayi
Xiong, Husheng
Li, Yufen
Guo, Tong
Peng, Bo
Fang, Chuanjun
Kang, Yan
Tan, Jinlin
Ma, Yu
author_facet Zhang, Dingmei
Zhong, Jiayi
Xiong, Husheng
Li, Yufen
Guo, Tong
Peng, Bo
Fang, Chuanjun
Kang, Yan
Tan, Jinlin
Ma, Yu
author_sort Zhang, Dingmei
collection PubMed
description This study aims to explore the relationship between the doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in the real-world setting, so as to preliminarily evaluate the protective effect induced by COVID-19 vaccination. We conducted a test-negative case-control study and recruited the test-positive cases and test-negative controls in the outbreak caused by Omicron BA.2 in April 2022 in Guangzhou, China. All the participants were 3 years and older. The vaccination status between the case group and the control group was compared in the vaccinated and all participants, respectively, to estimate the immune protection of inactivated COVID-19 vaccines. After adjusting for sex and age, compared with a mere single dose, full vaccination of inactivated COVID-19 vaccines (OR = 0.191, 95% CI: 0.050 to 0.727) and booster vaccination (OR = 0.091, 95% CI: 0.011 to 0.727) had a more superior protective effect. Compared with one dose, the second dose was more effective in males (OR = 0.090), as well as two doses (OR = 0.089) and three doses (OR = 0.090) among individuals aged 18–59. Whereas, when compared with the unvaccinated, one dose (OR = 7.715, 95% CI: 1.904 to 31.254) and three doses (OR = 2.055, 95% CI: 1.162 to 3.635) could contribute to the increased risk of Omicron infection after adjusting for sex and age. Meanwhile, by contrast with unvaccinated individuals, the result of increased risk was also manifested in the first dose in males (OR = 12.400) and one dose (OR = 21.500), two doses (OR = 1.890), and a booster dose (OR = 1.945) in people aged 18–59. In conclusion, the protective effect of full and booster vaccination with inactivated COVID-19 vaccines exceeded the incomplete vaccination, of which three doses were more effective. Nevertheless, vaccination may increase the risk of Omicron infection compared with unvaccinated people. This may result from the transmission traits of BA.2, the particularity and stronger protection awareness of the unvaccinated population, as well as the ADE effect induced by the decrease of antibody titers after a long time of vaccination. It is crucial to explore this issue in depth for the formulation of future COVID-19 vaccination strategies.
format Online
Article
Text
id pubmed-10053421
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100534212023-03-30 Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study Zhang, Dingmei Zhong, Jiayi Xiong, Husheng Li, Yufen Guo, Tong Peng, Bo Fang, Chuanjun Kang, Yan Tan, Jinlin Ma, Yu Vaccines (Basel) Article This study aims to explore the relationship between the doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in the real-world setting, so as to preliminarily evaluate the protective effect induced by COVID-19 vaccination. We conducted a test-negative case-control study and recruited the test-positive cases and test-negative controls in the outbreak caused by Omicron BA.2 in April 2022 in Guangzhou, China. All the participants were 3 years and older. The vaccination status between the case group and the control group was compared in the vaccinated and all participants, respectively, to estimate the immune protection of inactivated COVID-19 vaccines. After adjusting for sex and age, compared with a mere single dose, full vaccination of inactivated COVID-19 vaccines (OR = 0.191, 95% CI: 0.050 to 0.727) and booster vaccination (OR = 0.091, 95% CI: 0.011 to 0.727) had a more superior protective effect. Compared with one dose, the second dose was more effective in males (OR = 0.090), as well as two doses (OR = 0.089) and three doses (OR = 0.090) among individuals aged 18–59. Whereas, when compared with the unvaccinated, one dose (OR = 7.715, 95% CI: 1.904 to 31.254) and three doses (OR = 2.055, 95% CI: 1.162 to 3.635) could contribute to the increased risk of Omicron infection after adjusting for sex and age. Meanwhile, by contrast with unvaccinated individuals, the result of increased risk was also manifested in the first dose in males (OR = 12.400) and one dose (OR = 21.500), two doses (OR = 1.890), and a booster dose (OR = 1.945) in people aged 18–59. In conclusion, the protective effect of full and booster vaccination with inactivated COVID-19 vaccines exceeded the incomplete vaccination, of which three doses were more effective. Nevertheless, vaccination may increase the risk of Omicron infection compared with unvaccinated people. This may result from the transmission traits of BA.2, the particularity and stronger protection awareness of the unvaccinated population, as well as the ADE effect induced by the decrease of antibody titers after a long time of vaccination. It is crucial to explore this issue in depth for the formulation of future COVID-19 vaccination strategies. MDPI 2023-03-01 /pmc/articles/PMC10053421/ /pubmed/36992150 http://dx.doi.org/10.3390/vaccines11030566 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Dingmei
Zhong, Jiayi
Xiong, Husheng
Li, Yufen
Guo, Tong
Peng, Bo
Fang, Chuanjun
Kang, Yan
Tan, Jinlin
Ma, Yu
Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
title Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
title_full Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
title_fullStr Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
title_full_unstemmed Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
title_short Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
title_sort protective effect of inactivated covid-19 vaccines against omicron ba.2 infection in guangzhou: a test-negative case-control real-world study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053421/
https://www.ncbi.nlm.nih.gov/pubmed/36992150
http://dx.doi.org/10.3390/vaccines11030566
work_keys_str_mv AT zhangdingmei protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT zhongjiayi protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT xionghusheng protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT liyufen protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT guotong protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT pengbo protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT fangchuanjun protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT kangyan protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT tanjinlin protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy
AT mayu protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy